Alpha 2.0
Login Register
» Authors » Hatim Arishi

Hatim Arishi

Explore the profile of Hatim Arishi including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 9
Citations 494
Followers 0
Related Specialties
General Medicine
Critical Care
Pharmacology
Top 10 Co-Authors
Musharaf Sadat
Yaseen M Arabi
Samah Alqahtani
Hasan M Al-Dorzi
Jesna Jose
Ali Al Bshabshe
Abdulaziz Al-Dawood
Mohammed Almaani
Ghaleb A Almekhlafi
Yaseen Arabi
Published In
J Crit Care
Trials
JAMA
J Infect Public Health
Chest
Affiliations
Soon will be listed here.
Recent Articles
1.
Characteristics and outcomes of patients with Guillain-Barré syndrome who were admitted to the intensive care unit: a retrospective observational study
Alqahtani S, Al-Dorzi H, Arishi H, Peeran A, Humaid F, Alenezi F, et al.
J Int Med Res . 2024 Dec; 52(12):3000605241306655. PMID: 39719074
Objective: To evaluate characteristics and outcomes in critically ill patients with Guillain-Barré syndrome (GBS). Methods: Consecutive adults with GBS who required intensive care unit (ICU) admission at a tertiary-care hospital...
2.
Performance of Risk Assessment Models for VTE in Patients Who Are Critically Ill Receiving Pharmacologic Thromboprophylaxis: A Post Hoc Analysis of the Pneumatic Compression for Preventing VTE Trial
Al-Dorzi H, Arishi H, Al-Hameed F, Burns K, Mehta S, Jose J, et al.
Chest . 2024 Sep; 167(2):598-610. PMID: 39232999
Background: The diagnostic performance of the available risk assessment models for VTE in patients who are critically ill receiving pharmacologic thromboprophylaxis is unclear. Research Question: For patients who are critically...
3.
Statistical analysis plan for the replacing protein via enteral nutrition in a stepwise approach in critically ill patients (REPLENISH) randomized clinical trial
Arabi Y, Al-Dorzi H, Aldibaasi O, Sadat M, Jose J, Muharib D, et al.
Trials . 2024 May; 25(1):296. PMID: 38698442
Background: The optimal amount and timing of protein intake in critically ill patients are unknown. REPLENISH (Replacing Protein via Enteral Nutrition in a Stepwise Approach in Critically Ill Patients) trial...
4.
Replacing protein via enteral nutrition in a stepwise approach in critically ill patients: the REPLENISH randomized clinical trial protocol
Arabi Y, Al-Dorzi H, Sadat M, Muharib D, Algethamy H, Al-Hameed F, et al.
Trials . 2023 Jul; 24(1):485. PMID: 37518058
Background: Protein intake is recommended in critically ill patients to mitigate the negative effects of critical illness-induced catabolism and muscle wasting. However, the optimal dose of enteral protein remains unknown....
5.
Author's response: "Combination of norepinephrine with phenylephrine versus norepinephrine with vasopressin in critically ill patients with septic shock: A retrospective study"
Arishi H, Alqahtani S, Sadat M, Arabi Y
J Crit Care . 2022 Dec; 74:154240. PMID: 36543618
No abstract available.
6.
Author reply: Combination of norepinephrine with phenylephrine versus norepinephrine with vasopressin in critically ill patients with septic shock: A retrospective study
Arishi H, Alqahtani S, Sadat M, Arabi Y
J Crit Care . 2022 Oct; 73:154176. PMID: 36266194
No abstract available.
7.
Combination of norepinephrine with phenylephrine versus norepinephrine with vasopressin in critically ill patients with septic shock: A retrospective study
Arishi H, Alqahtani S, Tamim H, Sadat M, Alenezi F, Humaid F, et al.
J Crit Care . 2022 Jul; 72:154121. PMID: 35908329
Purpose: To evaluate the outcomes of patients with septic shock treated with a combination of norepinephrine with phenylephrine compared to norepinephrine with vasopressin. Materials And Methods: This was a retrospective...
8.
Outcomes associated with tocilizumab with or without corticosteroid versus dexamethasone for treatment of patients with severe to critical COVID-19 pneumonia
AlQahtani H, Albilal S, Mahmoud E, AlDibasi O, Alharbi A, Shamas N, et al.
J Infect Public Health . 2021 Dec; 15(1):36-41. PMID: 34883296
Introduction: Immunomodulators, including dexamethasone (DEX), have been recommended by the Infectious Disease Society of America (IDSA) to treat moderate, severe, and critical COVID-19. Tocilizumab (TCZ) was added to the treatment...
9.
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial
Angus D, Buzgau A, Cheng A, Higgins A, Hullegie S, Lawler P, et al.
JAMA . 2020 Sep; 324(13):1317-1329. PMID: 32876697
Importance: Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited. Objective: To determine whether hydrocortisone improves outcome for patients with severe COVID-19. Design, Setting, And Participants: An...